CN113694248B - Embolism microsphere based on soluble starch and preparation and application thereof - Google Patents
Embolism microsphere based on soluble starch and preparation and application thereof Download PDFInfo
- Publication number
- CN113694248B CN113694248B CN202111071157.XA CN202111071157A CN113694248B CN 113694248 B CN113694248 B CN 113694248B CN 202111071157 A CN202111071157 A CN 202111071157A CN 113694248 B CN113694248 B CN 113694248B
- Authority
- CN
- China
- Prior art keywords
- microsphere
- soluble
- starch
- embolism
- embolism microsphere
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/08—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0015—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0036—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0042—Materials resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F2/00—Processes of polymerisation
- C08F2/32—Polymerisation in water-in-oil emulsions
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F251/00—Macromolecular compounds obtained by polymerising monomers on to polysaccharides or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
Abstract
The invention provides an embolization microsphere based on soluble starch and a preparation method and application thereof. The embolism microsphere is prepared by soluble starch, an olefin polar monomer, an initiator and a cross-linking agent through an inverse suspension polymerization technology, wherein a continuous phase comprises an oil phase and a surfactant, and a dispersed phase comprises the soluble starch, the olefin polar monomer, the initiator and the cross-linking agent. According to the invention, the olefin polar monomer and the soluble starch are subjected to free radical grafting and then cross-linking to obtain the embolism microsphere, the embolism microsphere is rich in porous structure, pores extend towards the interior of the microsphere, so that the specific surface area of the embolism microsphere is larger, and the surface of the embolism microsphere has a large amount of hydrophilic polar groups, so that the embolism microsphere can generate electrostatic adsorption with a medicament, and a good medicament slow release effect of the embolism microsphere is realized. The embolism microsphere prepared by the invention has the drug loading of 191mg/g for doxorubicin hydrochloride and the entrapment rate of 96%, and effectively improves the drug loading and the entrapment rate of the starch embolism microsphere.
Description
Technical Field
The invention belongs to the technical field of microsphere preparation. More particularly, relates to an embolism microsphere based on soluble starch and preparation and application thereof.
Background
The Transcatheter Arterial Chemoembolization (TACE) plays an important role in the treatment of hepatocellular carcinoma, and is the first choice for the treatment of hepatocellular carcinoma in the middle and late stages at present. The embolism microsphere is used as a novel drug delivery and embolism system, and is embolized to a lesion part through an artery by adsorbing chemotherapeutic drugs, so that the drugs are slowly released, and the anticancer effect is achieved. Theoretically, the drug-loaded embolization microsphere can not only achieve higher local drug concentration and improve the treatment effect of TACE, but also reduce systemic toxicity, and gradually becomes a research focus and a key point in the field.
According to the degradability of raw materials, the embolism microsphere can be divided into biodegradable microsphere and non-biodegradable microsphere, the starch microsphere is a typical biodegradable microsphere, can be gradually degraded under the action of serum amylase in blood flow, and is considered as an ideal targeted drug carrier due to the advantages of large specific surface area, high efficiency, low toxicity, no immunogenicity, directional slow-release delivery system and the like. The reverse phase emulsion method is the most common method for preparing the starch microspheres, the synthesis process is simple, the reaction condition is mild, the control is easy, and the reaction reproducibility is good, for example, in patent CN201810440203.0, the heparin starch microsphere vascular embolization agent with the anti-tumor effect is prepared by the reverse phase emulsion method, but the embolization agent has no porous structure on the surface, the corresponding specific surface area is smaller, and the drug loading rate and the encapsulation rate are limited directly.
Therefore, the search for a starch microsphere with a porous structure to increase the drug loading and encapsulation efficiency has considerable necessity in the technical field of embolic microsphere preparation.
Disclosure of Invention
Aiming at the defects of the existing starch microspheres, the invention provides an embolization microsphere based on soluble starch and preparation and application thereof, so that the porous structure of the embolization microsphere is realized, and the drug loading rate and the encapsulation efficiency of the embolization microsphere are improved.
The invention aims to provide an embolization microsphere based on soluble starch.
Another object of the present invention is to provide a method for preparing the embolization microsphere.
It is still another object of the present invention to provide the use of the above embolic microspheres as/in the preparation of a drug delivery vehicle.
The above purpose of the invention is realized by the following technical scheme:
the invention provides an embolism microsphere based on soluble starch, which is prepared by using soluble starch, an olefin polar monomer, an initiator and a cross-linking agent through an inverse suspension polymerization technology, wherein a continuous phase comprises an oil phase and a surfactant, and a dispersed phase comprises the soluble starch, the olefin polar monomer, the initiator and the cross-linking agent.
According to the invention, the embolism microsphere of the soluble starch is analyzed and identified by utilizing infrared spectroscopy, and the characteristic peaks of carboxyl and starch are found to appear at the same time, which shows that the preparation method of the invention can successfully introduce carboxyl into the starch microsphere; the invention also adopts an optical microscope and a scanning electron microscope to characterize the embolism microsphere, the optical microscope picture shows that the embolism microsphere has uniform particle size distribution and good dispersibility, and the scanning electron microscope picture shows that the surface of the embolism microsphere is smooth and is porous after freeze-drying, so the specific surface area of the embolism microsphere is larger, and the high drug-loading rate and the high encapsulation rate of the microsphere can be effectively realized; in addition, the invention also utilizes a hemolysis experimental data graph to carry out quantitative calculation, finds that the hemolysis rate of the embolism microsphere is lower than 5 percent, accords with the national standard, shows that the embolism microsphere can not cause obvious hemolysis and has biological safety.
According to the invention, the olefin polar monomer and the soluble starch are subjected to free radical grafting and then cross-linking to obtain the embolism microsphere, the embolism microsphere is rich in porous structure, pores extend towards the interior of the microsphere, so that the specific surface area of the embolism microsphere is larger, and the surface of the embolism microsphere has a large amount of hydrophilic polar groups, so that the embolism microsphere can generate electrostatic adsorption with a medicament, and a good medicament slow release effect of the embolism microsphere is realized. The embolism microsphere prepared by the invention has the drug loading of 191mg/g for doxorubicin hydrochloride and the entrapment rate of 96%, and effectively improves the drug loading and the entrapment rate of the starch embolism microsphere.
Preferably, the mass ratio of the soluble starch to the olefin polar monomer to the initiator to the cross-linking agent is 10:5 to 10:0.1 to 0.3:0.1 to 0.2.
Most preferably, the mass ratio of the soluble starch, the olefin polar monomer, the initiator and the cross-linking agent is 10:10:0.2:0.1, see example 1.
Preferably, the olefin polar monomer comprises one or more of acrylic acid, methacrylic acid or 2-acrylamide-2-methylpropanesulfonic acid.
Most preferably, the olefinic polar monomer is acrylic acid, see example 1.
Preferably, the soluble starch comprises one or more of soluble corn starch, soluble tapioca starch, soluble potato starch or soluble sweet potato starch.
Preferably, the initiator comprises one or more of sodium persulfate, ammonium persulfate or potassium persulfate.
Preferably, the crosslinking agent comprises one or more of epichlorohydrin, N' -methylene-bisacrylamide, sodium trimetaphosphate or glutaraldehyde.
Preferably, the oil phase comprises one or more of n-hexane, liquid paraffin, vegetable oil, kerosene or cyclohexane.
Preferably, the surfactant comprises one or more of Span 80, tween 80, span 60 or tween 60.
Preferably, the mass ratio of the soluble starch, the oil phase and the surfactant is 1:10 to 20: 0.02-0.5.
Most preferably, the mass ratio of the soluble starch, the oil phase and the surfactant is 1:15:0.4, see example 1.
The invention also provides a preparation method of the embolism microsphere, which comprises the following steps:
s1, mixing an olefin polar monomer, an initiator, a cross-linking agent and a soluble starch solution to obtain a dispersed phase;
s2, mixing and heating the oil phase and the surfactant to obtain a continuous phase;
and S3, adding the dispersed phase obtained in the step S1 into the continuous phase obtained in the step S2, heating, standing, cleaning and drying to obtain the embolism microsphere based on the soluble starch.
Preferably, the preparation method of the soluble starch solution is specifically to dissolve soluble starch in water, and then add sodium hydroxide aqueous solution to mix, so as to obtain the soluble starch solution.
Preferably, the heating in step S3 is heating at 70 to 90 ℃.
More preferably, stirring is also performed during the heating in step S3, and the rotation speed of the stirring is 200 to 700r/min.
Preferably, the heating in step S4 is performed at 70-90 ℃ for 1-3 h.
More preferably, stirring is also performed during the heating in step S4, and the rotation speed of the stirring is 200 to 700r/min.
Preferably, the cleaning is performed by using an organic solvent and deionized water, specifically, the embolization microspheres are repeatedly washed by using the organic solvent, repeatedly washed by using the deionized water after centrifugation, and finally completed by centrifugation.
Further preferably, the organic solvent is one or more of absolute ethyl alcohol, ethyl acetate, petroleum ether or acetone.
The invention effectively improves the drug loading rate and the encapsulation efficiency of the starch embolism microsphere, so the application of the embolism microsphere in the preparation of drug delivery carrier is also within the protection scope of the invention.
Preferably, the drug comprises doxorubicin hydrochloride.
The invention has the following beneficial effects:
1) According to the invention, the olefin polar monomer and the soluble starch are subjected to free radical grafting and then cross-linking to obtain the embolism microsphere, the embolism microsphere is rich in porous structure, pores extend towards the interior of the microsphere, so that the specific surface area of the embolism microsphere is larger, and the surface of the embolism microsphere has a large amount of hydrophilic polar groups, so that the embolism microsphere can generate electrostatic adsorption with a medicament, and a good medicament slow release effect of the embolism microsphere is realized. The embolism microsphere prepared by the invention has the drug loading of 191mg/g for doxorubicin hydrochloride and the entrapment rate of 96%, and effectively improves the drug loading and the entrapment rate of the starch embolism microsphere.
2) The particle size of the embolism microsphere is 50-500 μm, the embolism microsphere is mainly distributed between 100-300 μm, the size of the embolism microsphere is in accordance with the ideal, the embolism microsphere is round and smooth, the surface is smooth, and the structure is stable.
3) The embolism microsphere has the advantages of biodegradability, biocompatibility, nontoxicity, no immunogenicity and the like, the hemolysis rate is lower than 5%, and the embolism microsphere conforms to the national standard, shows that the embolism microsphere can not cause obvious hemolysis and has biosafety.
4) The preparation method is simple, can be used for preparing a large amount of the compound in a short time, has high production efficiency and high industrial feasibility, and has good and wide application prospect.
Drawings
FIG. 1 is a graph comparing infrared absorption spectra.
Fig. 2 is a graph of the results of optical microscope scanning.
FIG. 3 is a scanning electron microscope result chart.
FIG. 4 is a graph of data from a hemolysis experiment.
Detailed Description
The invention is further described with reference to the drawings and the following detailed description, which are not intended to limit the invention in any way. Reagents, methods and apparatus used in the present invention are conventional in the art unless otherwise indicated.
Unless otherwise indicated, reagents and materials used in the following examples are commercially available.
EXAMPLE 1 preparation of embolic microspheres based on soluble starch
1. Preparation of embolizing microspheres
S1, dissolving 2g of soluble cassava starch in 20mL of water, adding 500 mu L of 0.2mol/L sodium hydroxide aqueous solution, and mixing and dissolving to obtain a soluble cassava starch solution;
s2, stirring and mixing acrylic acid, ammonium persulfate and N, N' -methylene bisacrylamide with the soluble cassava starch solution obtained in the step S1 to obtain a dispersion phase; (soluble tapioca starch: acrylic acid, ammonium persulfate, and N, N' -methylenebisacrylamide in a mass ratio of 10;
s3, mixing n-hexane and Span 80, heating to 85 ℃, and stirring at the rotating speed of 300r/min to obtain a continuous phase; (the mass ratio of the soluble tapioca starch, n-hexane and Span 80 satisfies 1;
s4, adding the dispersed phase obtained in the step S2 into the continuous phase obtained in the step S3, continuously heating at 85 ℃, stirring at a rotating speed of 300r/min, standing for layering after 1h, washing an oil phase remained on the surface of the microsphere with ethyl acetate, washing and separating with deionized water, and drying to obtain the embolism microsphere based on the soluble starch.
2. Embolic microsphere structure and performance testing
(1) The embolization microspheres obtained in this example and the soluble tapioca starch used as a raw material were analyzed and identified by infrared spectroscopy to obtain a comparative infrared absorption spectrum curve of fig. 1. As can be seen from FIG. 1, the infrared absorption spectrum curve of the embolization microsphere has characteristic peaks of carboxyl and starch at the same time, which indicates that the preparation method of the invention successfully introduces carboxyl into the starch microsphere.
(2) The embolization microspheres obtained in this example were characterized by an optical microscope and a scanning electron microscope to obtain fig. 2 and 3. As can be seen from FIG. 2, the particle size distribution of the embolism microsphere is uniform, and the dispersity is good; as can be seen from FIG. 3, the embolic microspheres have smooth surfaces and are porous after lyophilization; the specific surface area of the embolism microsphere is larger by combining with the figure 2 and the figure 3, which shows that the preparation method of the invention effectively realizes high drug loading and high encapsulation efficiency of the embolism microsphere.
(3) The embolized microspheres obtained in this example were subjected to a hemolysis test by first centrifuging fresh rat blood, collecting erythrocytes, and diluting with physiological saline to obtain a 10% erythrocyte suspension. Mixing normal saline and erythrocyte suspension according to the volume ratio of 1:1 as a negative control group; taking deionized water and erythrocyte suspension according to the volume ratio of 1:1 as a positive control group; the embolized microspheres were dispersed in the erythrocyte suspension at 1mg/mL, 3mg/mL, 5mg/mL, 10mg/mL, and 15mg/mL to prepare an experimental group. After the control group and the experimental group are incubated for 1h at 37 ℃, absorbance is detected at a wavelength of 540nm to obtain a hemolysis experiment data graph shown in figure 4, and the hemolysis rate of the embolization microsphere obtained by calculation according to the following formula is lower than 5%, which meets the national standard, and shows that the embolization microsphere does not cause obvious hemolysis and has biological safety.
Hemolysis rate% = (a) sample -A 0.9％NaCl )×100/(A DI water -A 0.9％NaCl )
EXAMPLE 2 preparation of embolic microspheres based on soluble starch
S1, dissolving 2g of soluble potato starch in 20mL of water, adding 500 mu L of 0.2mol/L sodium hydroxide aqueous solution, and mixing and dissolving to obtain a soluble potato starch solution;
s2, mixing methacrylic acid, sodium persulfate and sodium trimetaphosphate with the soluble potato starch solution obtained in the step S1 to obtain a dispersion phase; (the mass ratio of the soluble potato starch, the methacrylic acid, the sodium persulfate and the sodium trimetaphosphate is 10;
s3, mixing the liquid paraffin and Span 60, heating to 85 ℃, and stirring at the rotating speed of 300r/min to obtain a continuous phase; (the mass ratio of the soluble potato starch, the liquid paraffin and the Span 60 satisfies 1;
s4, adding the dispersed phase obtained in the step S2 into the continuous phase obtained in the step S3, continuously heating at 85 ℃, stirring at a rotating speed of 300r/min, standing for layering after 1h, washing an oil phase remained on the surface of the microsphere with ethyl acetate, washing and separating with deionized water, and drying to obtain the embolism microsphere based on the soluble starch.
Example 3 preparation of embolic microspheres based on soluble starch
S1, dissolving 2g of soluble corn starch in 20mL of water, adding 500 mu L of 0.2mol/L sodium hydroxide aqueous solution, mixing and dissolving to obtain a soluble corn starch solution;
s2, stirring and mixing acrylic acid, potassium persulfate and sodium trimetaphosphate with the soluble corn starch solution obtained in the step S1 to obtain a dispersion phase; (the mass ratio of the soluble corn starch, the acrylic acid, the potassium persulfate and the sodium trimetaphosphate is 10;
s3, mixing kerosene and Span 80, heating to 90 ℃, and stirring at the rotating speed of 200r/min to obtain a continuous phase; (the mass ratio of the soluble corn starch, the kerosene and the Span 80 satisfies 1;
s4, adding the dispersed phase obtained in the step S2 into the continuous phase obtained in the step S3, continuously heating at 85 ℃, stirring at a rotating speed of 300r/min, standing for layering after 1h, washing an oil phase remained on the surface of the microsphere with ethyl acetate, washing and separating with deionized water, and drying to obtain the embolism microsphere based on the soluble starch.
Example 4 preparation of embolic microspheres based on soluble starch
S1, dissolving 2g of soluble sweet potato starch in 20mL of water, adding 500 mu L of 0.2mol/L sodium hydroxide aqueous solution, mixing and dissolving to obtain a soluble sweet potato starch solution;
s2, stirring and mixing acrylic acid, ammonium persulfate and N, N' -methylene bisacrylamide with the soluble sweet potato starch solution obtained in the step S1 to obtain a dispersion phase; (soluble sweet potato starch: acrylic acid, ammonium persulfate, N' methylene bisacrylamide in a mass ratio of 10;
s3, mixing the vegetable oil and the Tween 80, heating to 70 ℃, and stirring at the rotating speed of 700r/min to obtain a continuous phase; (the mass ratio of the soluble sweet potato starch, the vegetable oil and the Tween 80 satisfies 1;
s4, adding the dispersed phase obtained in the step S2 into the continuous phase obtained in the step S3, continuously heating at 70 ℃, stirring at a rotating speed of 700r/min, standing for layering after 1h, washing an oil phase remained on the surface of the microsphere with ethyl acetate, washing and separating with deionized water, and drying to obtain the embolism microsphere based on the soluble starch.
Example 5A method for preparing embolic microspheres based on soluble starch
S1, dissolving 2g of soluble sweet potato starch in 20mL of water, adding 500 mu L of 0.2mol/L sodium hydroxide aqueous solution, mixing and dissolving to obtain a soluble sweet potato starch solution;
s2, stirring and mixing acrylic acid, 2-acrylamide-2-methylpropanesulfonic acid, ammonium persulfate and epoxy chloropropane with the soluble sweet potato starch solution obtained in the step S1 to obtain a dispersion phase; (the mass ratio of the soluble sweet potato starch to acrylic acid: 2-acrylamide-2-methylpropanesulfonic acid to ammonium persulfate to epichlorohydrin is 10;
s3, mixing cyclohexane and Tween 60, heating to 85 ℃, and stirring at the rotating speed of 300r/min to obtain a continuous phase; (the mass ratio of the soluble sweet potato starch, the cyclohexane and the Tween 60 satisfies 1;
s4, adding the dispersed phase obtained in the step S2 into the continuous phase obtained in the step S3, continuously heating at 90 ℃, stirring at a rotating speed of 200r/min, standing for layering after 1h, washing an oil phase remained on the surface of the microsphere with ethyl acetate, washing and separating with deionized water, and drying to obtain the embolism microsphere based on the soluble starch.
Comparative example 1
The preparation method is the same as that of example 1, except that the mass ratio of the soluble tapioca starch to acrylic acid in step S2 is 10:2.5.
comparative example 2
The preparation method is the same as that of example 1, except that the mass ratio of the soluble tapioca starch to acrylic acid in step S2 is 10:20.
comparative example 3
The preparation method is the same as that of example 2, except that the mass ratio of the soluble potato starch to the methacrylic acid in the step S2 is 10:2.5.
comparative example 4
The preparation method is the same as that of example 2, except that the mass ratio of the soluble potato starch to the methacrylic acid in the step S2 is 10:20.
comparative example 5
The preparation method is the same as that of example 5, except that the mass ratio of the soluble sweet potato starch to the acrylic acid and the 2-acrylamide-2-methylpropanesulfonic acid in the step S2 is 10:2.5:1.
comparative example 6
The preparation method is the same as that of example 5, except that the mass ratio of the soluble sweet potato starch to the acrylic acid and the 2-acrylamide-2-methylpropanesulfonic acid in the step S2 is 10:10:10.
comparative example 7
The same preparation method as in example 1 was repeated except that the heating temperature in steps S3 and S4 was 40 ℃.
Comparative example 8
The same preparation method as in example 1 except that the heating temperature in steps S3 and S4 was 120 ℃.
Comparative example 9
The preparation process is the same as that of example 1, except that the stirring speed in steps S3 and S4 is 100r/min.
Comparative example 10
The preparation process is the same as that of example 1, except that the stirring speed in steps S3 and S4 is 900r/min.
Examples of the experiments
Respectively dispersing 50mg of the embolization microspheres prepared in examples 1 to 5 and comparative examples 1 to 10 into 5mL of doxorubicin hydrochloride solution of 2mg/mL, shaking at a rotation speed of 100rpm/min for 24h, and respectively calculating the drug loading rate and the encapsulation rate of the embolization microspheres according to the drug loading rate = the drug mass in the embolization microspheres/the quality of the embolization microspheres and the encapsulation rate = the drug mass in the embolization microspheres/the drug input amount × 100% by detecting the concentration of the remaining doxorubicin hydrochloride in the solution, wherein the results are shown in table 1:
TABLE 1
As can be seen from Table 1, the drug loading and encapsulation efficiencies of examples 1-5 are both high, especially the best of example 1; while comparative examples 1 to 10, in which the kind, amount or experimental parameters of the raw materials were changed, could not effectively prepare microspheres, or were not suitable for use as embolization microspheres in practical applications. The invention shows that the medicine carrying amount of the prepared embolism microsphere for the doxorubicin hydrochloride reaches 191mg/g, the entrapment rate reaches 96% by specifically controlling the type and the amount of the raw materials and the parameters of each step, and the medicine carrying amount and the entrapment rate of the starch embolism microsphere are effectively improved.
In conclusion, the embolism microsphere prepared by the invention is rich in porous structure, the pores extend to the interior of the microsphere, so that the specific surface area of the embolism microsphere is larger, and the surface of the embolism microsphere is provided with a large number of hydrophilic polar groups, so that the embolism microsphere can generate electrostatic adsorption with a medicament, and a good medicament slow-release effect of the embolism microsphere is realized. The embolism microsphere prepared by the invention has the drug loading of 191mg/g for doxorubicin hydrochloride and the entrapment rate of 96%, and effectively improves the drug loading and the entrapment rate of the starch embolism microsphere.
The above embodiments are preferred embodiments of the present invention, but the present invention is not limited to the above embodiments, and any other changes, modifications, substitutions, combinations, and simplifications which do not depart from the spirit and principle of the present invention should be construed as equivalents thereof, and all such modifications are intended to be included in the scope of the present invention.
Claims (4)
1. A preparation method of embolism microsphere based on soluble starch is characterized by comprising the following steps:
s1, dissolving soluble cassava starch in water, and then adding a sodium hydroxide aqueous solution for mixing to obtain a soluble cassava starch solution;
s2, stirring and mixing acrylic acid, ammonium persulfate and N, N' -methylene bisacrylamide with the soluble cassava starch solution obtained in the step S1 to obtain a dispersion phase; wherein the mass ratio of the soluble cassava starch to the acrylic acid to the ammonium persulfate to the N, N' -methylene bisacrylamide is 10:10:0.2:0.1;
s3, mixing n-hexane and Span 80, heating to 85 ℃, and stirring at the rotating speed of 300r/min to obtain a continuous phase; wherein the mass ratio of the soluble cassava starch to the normal hexane to the Span 80 is 1:15:0.4;
and S4, adding the dispersed phase obtained in the step S2 into the continuous phase obtained in the step S3, continuously heating at 85 ℃, stirring at a rotating speed of 300r/min, standing for layering after 1h, washing an oil phase remained on the surface of the microsphere with ethyl acetate, washing and separating with deionized water, and drying to obtain the embolism microsphere based on the soluble starch.
2. An embolization microsphere prepared by the method of claim 1.
3. Use of an embolic microsphere as in claim 2 for the preparation of a drug delivery vehicle.
4. The use of claim 3, wherein the medicament comprises doxorubicin hydrochloride.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111071157.XA CN113694248B (en) | 2021-09-13 | 2021-09-13 | Embolism microsphere based on soluble starch and preparation and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111071157.XA CN113694248B (en) | 2021-09-13 | 2021-09-13 | Embolism microsphere based on soluble starch and preparation and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113694248A CN113694248A (en) | 2021-11-26 |
| CN113694248B true CN113694248B (en) | 2023-03-17 |
Family
ID=78660266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111071157.XA Active CN113694248B (en) | 2021-09-13 | 2021-09-13 | Embolism microsphere based on soluble starch and preparation and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113694248B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114057940B (en) * | 2021-12-02 | 2023-11-03 | 中山大学 | Biodegradable carbomer core-shell structure polymer microsphere and preparation method and application thereof |
| CN114106252B (en) * | 2021-12-13 | 2022-11-08 | 科睿驰（深圳）医疗科技发展有限公司 | Color-developing embolism microsphere and preparation method thereof |
| CN114392384B (en) * | 2021-12-24 | 2023-04-11 | 河南驼人医疗器械研究院有限公司 | Method for preparing high drug-loading rate embolism microsphere and collecting device |
| CN114392383A (en) * | 2022-01-18 | 2022-04-26 | 上海方润介入器械有限公司 | Degradable embolism microsphere and preparation method thereof |
| CN114377191A (en) * | 2022-01-18 | 2022-04-22 | 上海方润介入器械有限公司 | Degradable embolism microsphere and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101695477A (en) * | 2009-10-21 | 2010-04-21 | 甘肃农业大学 | Method for preparing potato starch medicament carrier microspheres |
| CN103977458A (en) * | 2014-05-28 | 2014-08-13 | 南京弗来明医疗器械有限公司 | Polyhydroxyl polymer embolized microsphere and preparation process thereof |
| CN108620004A (en) * | 2018-05-14 | 2018-10-09 | 河南工业大学 | A kind of starch/PVA complex microspheres and preparation method thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2551164T3 (en) * | 2000-03-24 | 2015-11-16 | Biosphere Medical, Inc. | Microspheres for active embolization |
| TWI293317B (en) * | 2003-12-31 | 2008-02-11 | Ind Tech Res Inst | Method for preparing polymer microspheres by aqueous phase-aqueous phase emulsion process |
| CN101125225A (en) * | 2007-08-10 | 2008-02-20 | 苏州迦俐生生物医药科技有限公司 | Microsphere type embolic agent and preparation technology thereof |
| CN101670095B (en) * | 2009-04-13 | 2012-05-23 | 北京大学 | Pharmaceutical composition for treating embolism and preparation method thereof |
| CN101716349B (en) * | 2009-12-16 | 2012-02-08 | 北京大学 | Medicine composite used for embolotherapy and acesodyne and preparation method thereof |
| CN102603976B (en) * | 2012-02-26 | 2013-05-01 | 河南工业大学 | Preparation method of quaternary phosphonium cation starch microspheres |
| WO2014036681A1 (en) * | 2012-09-04 | 2014-03-13 | 西能化工科技(上海)有限公司 | Heat-expandable microspheres, preparation method and use thereof |
| CN104177642B (en) * | 2014-08-13 | 2017-01-11 | 浙江大学 | Expanded bed adsorption matrix and preparation method thereof |
| CN109422886B (en) * | 2017-08-22 | 2020-11-06 | 中国石油化工股份有限公司 | Anion-doped starch microsphere material and preparation method and application thereof |
| CN108070060B (en) * | 2017-12-29 | 2020-09-08 | 广州五行材料科技有限公司 | Microsphere powder of micron-level high-crosslinked polymer and preparation method and application thereof |
| CN110201215B (en) * | 2019-06-11 | 2021-07-30 | 科睿驰（深圳）医疗科技发展有限公司 | Gradient cross-linked high-elasticity embolism microsphere and preparation process thereof |
-
2021
- 2021-09-13 CN CN202111071157.XA patent/CN113694248B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101695477A (en) * | 2009-10-21 | 2010-04-21 | 甘肃农业大学 | Method for preparing potato starch medicament carrier microspheres |
| CN103977458A (en) * | 2014-05-28 | 2014-08-13 | 南京弗来明医疗器械有限公司 | Polyhydroxyl polymer embolized microsphere and preparation process thereof |
| CN108620004A (en) * | 2018-05-14 | 2018-10-09 | 河南工业大学 | A kind of starch/PVA complex microspheres and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 交联共聚淀粉微球对阿司匹林吸附性能的研究;姚少芳等;《贵阳医学院学报》;20110430(第02期);全文 * |
| 离子交换型栓塞微球及其载平阳霉素的制备与性质研究;袁惠燕等;《北京大学学报(医学版)》;20090418(第02期);全文 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113694248A (en) | 2021-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113694248B (en) | Embolism microsphere based on soluble starch and preparation and application thereof | |
| CN103341172B (en) | Dual-hole polysaccharide microspheres, preparation method and purpose thereof | |
| CN103374143B (en) | A kind of super large pore polymer microsphere and preparation method thereof | |
| EP3050902B1 (en) | Process for producing porous cellulose beads using alkali aqueous solution, and porous cellulose beads produced by this process | |
| CN105534952B (en) | A kind of preparation method of nucleocapsid composite porous microspheres | |
| CN1903890A (en) | Preparation method of super large pore polymer microsphere and its product | |
| JP6889265B2 (en) | Chromatographic medium to which microspheres are bound, and a method for producing the same | |
| CN102443088A (en) | Uniform-size small-particle-size super-macroporous polymer microspheres and preparation method thereof | |
| CN106268703A (en) | DNA immunization adsorbent and preparation method thereof | |
| CN112023904B (en) | Quickly synthesized adsorbent PACP-MnO2Nano microsphere and preparation method and application thereof | |
| CN103205081A (en) | Preparation method for temperature-sensitive chitosan-based polyelectrolyte composite micelle | |
| CN109749024A (en) | A kind of conductive porous hydrogel and preparation method thereof | |
| WO2016167268A1 (en) | Method for producing porous cellulose beads, and adsorbent using same | |
| CN112915254B (en) | Grafted long-alkyl chitosan/sodium tripolyphosphate gel and preparation method and application thereof | |
| JP6440320B2 (en) | Method for producing porous cellulose beads and adsorbent using the same | |
| CN117101616A (en) | Molecularly imprinted polymer adsorption material based on metal-organic framework, and preparation method and application thereof | |
| JPS6313726B2 (en) | ||
| CN1887273A (en) | Prepn process of polysaccharide vitreous particle | |
| JP2002542318A (en) | Method for producing monodisperse polymer particles | |
| CN101402029B (en) | Homogeneous crosslinking beta-cyclodextrin/wolfram carbine composite microsphere and method of producing the same | |
| CN113896910A (en) | Nano starch-based microgel microspheres and preparation method and application thereof | |
| JP6442409B2 (en) | Method for producing porous cellulose beads | |
| CN114432251A (en) | Starch-sodium alginate embolism microsphere capable of carrying medicine and preparation method and application thereof | |
| CN113801268B (en) | Preparation method of chitosan modified acrylic-based microspheres | |
| JP2745418B2 (en) | Method for producing porous polymer particles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |